Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.

Cleveland Clinic Fecal Incontinence Score (CCFIS) Multiple sclerosis (MS) Rome III criteria fecal incontinence (FC) functional constipation (FC) neurogenic bowel dysfunctions (NBDs) percutaneous posterior tibial nerve stimulation (PTNS)

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 13 11 2020
medline: 25 2 2023
entrez: 12 11 2020
Statut: ppublish

Résumé

Neurogenic bowel dysfunctions (NBDs) in the form of both fecal incontinence (FI) and functional constipation (FC) are frequent in multiple sclerosis (MS) patients and significantly affect their quality of life. Therapeutic options are limited. To investigate effectiveness of percutaneous posterior tibial nerve stimulation (PTNS) in MS patients suffering from FI and FC. Prevalence and severity of FI and FC were prospectively collected among MS patients undergoing 12 weeks of PTNS for neurogenic bladder. The Cleveland Clinic Fecal Incontinence Score (CCFIS) and the Rome III criteria were used to define FI and FC, respectively. Subjective treatment satisfaction was estimated using the Benefit Satisfaction and Willingness to Continue (BSWC) questionnaire. A total of 60 patients undergoing PTNS suffered from NBDs (25 FI+/FC+, 5 FI+/FC-, 30 FI-/FC+). Median CCFIS decreased after PTNS from 12.0 (11.0-13.0) to 8.5 (7.0-11.0, PTNS represents a valid minimally invasive alternative treatment for MS patients suffering from NBDs.

Sections du résumé

BACKGROUND
Neurogenic bowel dysfunctions (NBDs) in the form of both fecal incontinence (FI) and functional constipation (FC) are frequent in multiple sclerosis (MS) patients and significantly affect their quality of life. Therapeutic options are limited.
OBJECTIVE
To investigate effectiveness of percutaneous posterior tibial nerve stimulation (PTNS) in MS patients suffering from FI and FC.
METHODS
Prevalence and severity of FI and FC were prospectively collected among MS patients undergoing 12 weeks of PTNS for neurogenic bladder. The Cleveland Clinic Fecal Incontinence Score (CCFIS) and the Rome III criteria were used to define FI and FC, respectively. Subjective treatment satisfaction was estimated using the Benefit Satisfaction and Willingness to Continue (BSWC) questionnaire.
RESULTS
A total of 60 patients undergoing PTNS suffered from NBDs (25 FI+/FC+, 5 FI+/FC-, 30 FI-/FC+). Median CCFIS decreased after PTNS from 12.0 (11.0-13.0) to 8.5 (7.0-11.0,
CONCLUSION
PTNS represents a valid minimally invasive alternative treatment for MS patients suffering from NBDs.

Identifiants

pubmed: 33179574
doi: 10.1177/1352458520972267
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1577-1584

Auteurs

Rosaria Sacco (R)

Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano, Switzerland.

Andrea Braga (A)

Department of Obstetrics and Gynecology, EOC-Beata Vergine Hospital, Mendrisio, Switzerland.

Giulio Disanto (G)

Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano, Switzerland.

Giuseppe Alessandro Digesu (GA)

Department of Urogynaecology, Imperial College Healthcare NHS Trust, London, UK.

Paolo Maino (P)

Anestesiologia, Ospedale Regionale di Lugano, Lugano, Switzerland/Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Eva Koetsier (E)

Anestesiologia, Ospedale Regionale di Lugano, Lugano, Switzerland.

Giorgio Caccia (G)

Department of Obstetrics and Gynecology, EOC-Beata Vergine Hospital, Mendrisio, Switzerland.

Maurizio Serati (M)

Department of Obstetrics and Gynecology, EOC-Beata Vergine Hospital, Mendrisio, Switzerland.

Julien Renard (J)

Urology, Ospedale Regionale di Bellinzona e Valli-San Giovanni Bellinzona, Bellinzona, Switzerland.

Claudio Gobbi (C)

Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano, Switzerland/Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Chiara Zecca (C)

Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano, Switzerland/Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH